ESC 365 - Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

ESC Premium Access

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

Session: Atrial fibrillation: risks and management

Topic: Epidemiology, Prognosis, Outcome

Speaker: Mr P. Nielsen (Aalborg, DK)

Event: ESC Congress 2021 - The Digital Experience

Congress Session

About the speaker

Mr Peter Bronnum Nielsen

Aalborg University Hospital, Aalborg (Denmark)

2 presentations

0 follower

4 more presentations in this session

Risk of dementia according to smoking cessation after newly diagnosed atrial fibrillation: a nationwide cohort study

Speaker: Doctor H. Lee (Seoul, KR)

Beta-blocker treatment in atrial fibrillation with chronic obstructive pulmonary disease: a Danish nationwide study from 1995 to 2015

Speaker: Mr C. Benson (Copenhagen, DK)

Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study

Speaker: Doctor S. Lee (Seoul, KR)

Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts - the BiomarCaRE project.

Speaker: Professor D. Rothenbacher (Ulm, DE)

Access the full session

Atrial fibrillation: risks and management

Speakers: Mr P. Nielsen, Doctor H. Lee, Mr C. Benson, Doctor S. Lee, Professor D. Rothenbacher

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

EHRA Premium Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

EHRA Premium Access

EHRA position paper on leadless pacing and extravascular defibrillators.

3 April 2022

ESC Premium Access

Acute safety and performance outcomes from the inspIRE trial using a novel pulsed field ablation system for the treatment of paroxysmal atrial fibrillation

27 August 2021

This platform is supported by